A 22-year-old soldier presented with vivax malaria after extended travel in Afghanistan. Compliant with atovaquone/proguanil in country, he discontinued prophylaxis immediately upon departure. This case raises important issues regarding prophylactic choice and compliance during travel to Plasmodium vivax endemic locations and primaquine's registration status for prophylaxis and use by practitioners.
No takes yet. Share an insight, caveat, or question.
Maguire et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: